Clinical Trials · NCT00987168

Sandostatine® LP and Hyperinsulinism

CompletedPhase 2Octreotide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
10
Start date
May 2009
Locations
1 site, France
Primary endpoint
Glycemia > or equal to 3 mmol/L, before and after 4 meals +Midnight + 4 am
View Octreotide compound reference